NasdaqGS:RPRXPharmaceuticals
Assessing Royalty Pharma (RPRX) Valuation After Teva Autoimmune Funding Partnership Attracts Fresh Attention
Why Royalty Pharma’s latest funding deal matters
Royalty Pharma (RPRX) has moved into focus after announcing a funding partnership with Teva Pharmaceuticals to speed up clinical development of an anti IL 15 antibody for autoimmune diseases.
This agreement highlights how Royalty Pharma deploys capital into biopharma projects, with investors watching how the Teva collaboration fits into its existing portfolio of marketed therapies and development stage candidates.
See our latest analysis for...